CoChat
Sign Up
Cited by 30Gut microbiota and healthCancer Research and TreatmentsCancer Immunotherapy and Biomarkers

Tumor-resident microbes: the new kids on the microenvironment block

Open access
Li, Le, Chandra, Vidhi, McAllister, Florencia·2024·Trends in Cancer
DOI 10.1016/j.trecan.2023.12.002PMC PMC11006566
Open this paper in CoChat — free account

Abstract

Tumor-resident microbes (TRM) are an integral component of the tumor microenvironment (TME). TRM can influence tumor growth, distant dissemination, and response to therapies by interfering with molecular pathways in tumor cells as well as with other components of the TME. Novel technologies are improving the identification and visualization of cell type-specific microbes in the TME. The mechanisms that mediate the role of TRM at the primary tumors and metastatic sites are being elucidated. This knowledge is providing novel perspectives for targeting microbes or using microbial interventions for cancer interception or therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2023.12.002

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tumor microenvironment microbes produce pro-proliferative metabolites.

    “These microbes interact with both tumor and immune cells, influencing tumor dynamics by modulating immune responses, producing pro-proliferative metabolites, and reshaping the structural and biochemical landscape of the TME [38–40]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [40]

    The 'Effect of tumor microbes on immunity' section says tumor-resident microbes produce metabolites and can induce inflammatory mediators that promote tumor development. It does not say that the metabolites they produce are pro-proliferative; the proliferation it describes is of immune cells driven by inflammatory mediators. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • Tumor microenvironment microbes influence tumor dynamics by modulating immune responses.

    “These microbes interact with both tumor and immune cells, influencing tumor dynamics by modulating immune responses, producing pro-proliferative metabolites, and reshaping the structural and biochemical landscape of the TME [38–40]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [40]

  • Tumor microenvironment microbes interact with both tumor and immune cells.

    “These microbes interact with both tumor and immune cells, influencing tumor dynamics by modulating immune responses, producing pro-proliferative metabolites, and reshaping the structural and biochemical landscape of the TME [38–40]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [40]

  • Tumor microenvironment microbes reshape the structural and biochemical landscape of the tumor microenvironment.

    “These microbes interact with both tumor and immune cells, influencing tumor dynamics by modulating immune responses, producing pro-proliferative metabolites, and reshaping the structural and biochemical landscape of the TME [38–40]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [40]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 68

  1. [1]Nicholson JK (2012) Host–gut microbiota metabolic interactions. Science 336, 1262– 1267 22674330
  2. [2]Zheng D (2020) Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492– 506 32433595 PMC7264227
  3. [3]Turnbaugh PJ (2007) The human microbiome project. Nature 449, 804– 810 17943116 PMC3709439
  4. [4]Liu Q (2020) Staphylococcus epidermidis contributes to healthy maturation of the nasal microbiome by stimulating antimicrobial peptide production. Cell Host Microbe 27, 68– 78 31866425 PMC10988655
  5. [5]Ivanov II (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485– 498 19836068 PMC2796826
  6. [8]Cullin N (2021) Microbiome and cancer. Cancer Cell 39, 1317– 1341 34506740
  7. [9]Sepich-Poore GD (2021) The microbiome and human cancer. Science 371, eabc4452 PMC8767999 33766858
  8. [10]Anderson NM and Simon MC (2020) The tumor microenvironment. Curr. Biol 30, R921– R925 32810447 PMC8194051
  9. [12]Marshall BJ and Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311– 1315 6145023
  10. [13]IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994) Schistosomes, Liver Flukes and Helicobacter pylori, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 61. International Agency for Research on Cancer PMC7681621 7715068
  11. [14]Javaheri A (2016) Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat. Microbiol 2, 16189 27748768
  12. [15]Arthur JC (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120– 123 22903521 PMC3645302
  13. [18]Pleguezuelos-Manzano C (2020) Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature 580, 269– 273 32106218 PMC8142898
  14. [20]Wu S (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med 15, 1016– 1022 19701202 PMC3034219
  15. [21]Chung L (2018) Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23, 203– 214 29398651 PMC5954996
  16. [22]Castellarin M (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299– 306 22009989 PMC3266037
  17. [23]Kostic AD (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207– 215 23954159 PMC3772512
  18. [24]Rubinstein MR (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195– 206 23954158 PMC3770529
  19. [25]Abed J (2016) Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 20, 215– 225 27512904 PMC5465824
  20. [26]Yang Y (2017) Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-kappab, and up-regulating expression of microRNA-21. Gastroenterology 152, 851– 866 27876571 PMC5555435
  21. [27]Parhi L (2020) Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat. Commun 11, 3259 32591509 PMC7320135
  22. [28]Mitsuhashi K (2015) Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6, 7209– 7220 25797243 PMC4466679
  23. [29]Qiao H (2022) Association of intratumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol. 8, 1301– 1309 35834269 PMC9284409
  24. [30]Fu A (2022) Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185, 1356– 1372 35395179
  25. [31]Le Noci V (2018) Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases. Cell Rep. 24, 3528– 3538 30257213
  26. [32]Rajasekaran K (2021) The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis. Oral Oncol. 117, 105305 33905914
  27. [33]Chiba A (2020) Neoadjuvant chemotherapy shifts breast tumor microbiota populations to regulate drug responsiveness and the development of metastasis. Mol. Cancer Res 18, 130– 139 31628201 PMC9153322
  28. [34]Li Z (2021) Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma. BMC Microbiol. 21, 301 34717543 PMC8556942
  29. [35]Bullman S (2017) Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443– 1448 29170280 PMC5823247
  30. [36]Chen G (2023) Fusobacterium nucleatum outer membrane vesicles activate autophagy to promote oral cancer metastasis. J. Adv. Res, Published online April 13, 2023. 10.1016/j.jare.2023.04.002 PMC10834801 37059221 · DOI
  31. [37]Chen Y (2020) Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics 10, 323– 339 31903123 PMC6929621
  32. [38]Zhang Y (2022) Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-κB/ICAM1 axis. Gut Microbes 14, 2038852 35220887 PMC8890384
  33. [39]Guo S (2020) Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16. Gut 70, 1507– 1519 33172926
  34. [40]Yang M (2023) Targeting Fusobacterium nucleatum through chemical modifications of host-derived transfer RNA fragments. ISME J. 17, 880– 890 37005460 PMC10202947
  35. [41]Bertocchi A (2021) Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell 39, 708– 724 33798472
  36. [42]Carloni S (2021) Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science 374, 439– 448 34672740
  37. [43]Qiao H (2022) Multi-omics integration reveals the crucial role of Fusobacterium in the inflammatory immune microenvironment in head and neck squamous cell carcinoma. Microbiol. Spectr 10, e0106822 35862975 PMC9431649
  38. [44]Liu Z (2023) Multi-omics analysis reveals intratumor microbes as immunomodulators in colorectal cancer. Microbiol. Spectr 11, e0503822 36786568 PMC10100960
  39. [45]Mima K (2015) Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, 653– 661 26181352 PMC4537376
  40. [47]Zhu G (2021) Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. Eur. J. Cancer 151, 25– 34 33962358 PMC8184628
  41. [48]Sheng D (2023) The interaction between intratumoral microbiome and immunity is related to the prognosis of ovarian cancer. Microbiol. Spectr 11, e0354922 36975828 PMC10100779
  42. [49]Serna G (2020) Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann. Oncol 31, 1366– 1375 32569727 PMC7542577
  43. [50]Peng R (2022) Gastric microbiome alterations are associated with decreased CD8+ tissue-resident memory T cells in the tumor microenvironment of gastric cancer. Cancer Immunol. Res 10, 1224– 1240 35881964
  44. [51]Shi Y (2020) Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J. Exp. Med 217, e20192282 32142585 PMC7201921
  45. [52]Wang H (2022) The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 34, 581– 594 35278352
  46. [54]Jin C (2019) Commensal microbiota promote lung cancer development via γδ T Cells. Cell 176, 998– 1013 30712876 PMC6691977
  47. [55]Tan Q (2022) Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes 14, 2073785 35549648 PMC9116393
  48. [56]Xu C (2021) Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes 13, 1980347 34632963 PMC8510564
  49. [57]Alam A (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell 40, 153– 167 35120601 PMC8847236
  50. [58]Perry LM (2023) Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis. J. Immunother. Cancer 11, e004285 36599469 PMC9815021
  51. [59]Galeano Nino JL (2022) Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611, 810– 817 36385528 PMC9684076
  52. [60]Fan JX (2022) Progress of engineered bacteria for tumor therapy. Adv. Drug Deliv. Rev 185, 114296 35439571
  53. [61]Kalaora S (2021) Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138– 143 33731925 PMC9717498
  54. [62]Savage TM (2023) Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Sci. Adv 9, eadc9436 36888717 PMC9995032
  55. [65]Chowdhury S (2019) Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med 25, 1057– 1063 31270504 PMC6688650
  56. [66]Mohindroo C (2021) Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 10, 5041– 5050 34250759 PMC8335807
  57. [67]Fulop DJ (2023) Association of antibiotic receipt with survival among patients with metastatic pancreatic ductal adenocarcinoma receiving chemotherapy. JAMA Netw. Open 6, e234254 36951863 PMC10037151
  58. [68]Zhang X (2021) Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis. Sci. Rep 11, 14024 34234229 PMC8263554
  59. [70]Pederzoli F (2021) Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab? Eur. Urol 80, 319– 322 34053782
  60. [71]Iida N (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967– 970 24264989 PMC6709532
  61. [73]Zhang S (2019) Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J. Exp. Clin. Cancer Res 38, 14 30630498 PMC6327560
  62. [74]LaCourse KD (2022) The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 41, 111625 36384132 PMC10790632
  63. [75]Geller LT (2017) Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156– 1160 28912244 PMC5727343
  64. [76]Gao Y (2021) Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct. Target. Ther 6, 398 34795206 PMC8602417
  65. [77]Cercek A (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med 386, 2363– 2376 35660797 PMC9492301
  66. [79]Jiang SS (2023) Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781– 797 37130518
  67. [80]Hamada T (2018) Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol. Res 6, 1327– 1336 30228205 PMC6215508
  68. [81]Fluckiger A (2020) Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936– 942 32820119

Cited by

Sorted by citations

Authors
Li, L., Chandra, V., & McAllister, F.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
McAllister, Florencia
ORCID
Venue
Trends in Cancer
Publisher
Elsevier BV
Published
2024-04
Volume
10
Issue
4
Pages
347-355
ISSN
  • 2405-8025 (ISSN-L)
  • 2405-8033
DOI
10.1016/j.trecan.2023.12.002
PMC
PMC11006566
OpenAlex
W4392055196
Cited by
30
References
14
Citations by year
2026: 11 · 2025: 13 · 2024: 6
FWCI
1.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Trends in cancer (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • Andrew Sabin Family Foundation
  • NCI
  • V Foundation
  • Pancreatic Cancer Action Network
  • CPRIT
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
tumor microenvironment, microbiome, metastasis, microbial interventions, cancer therapy response
MeSH terms
Humans, Immunotherapy, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review